• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: INTERVASCULAR SAS INTERGARD WOVEN AORTIC ARCH; VASCULAR GRAFT PROSTHESIS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

INTERVASCULAR SAS INTERGARD WOVEN AORTIC ARCH; VASCULAR GRAFT PROSTHESIS Back to Search Results
Model Number HEWAA2410080810/1
Device Problem Manufacturing, Packaging or Shipping Problem (2975)
Patient Problem Blood Loss (2597)
Event Date 11/24/2015
Event Type  Injury  
Manufacturer Narrative
A review of the complaint device history records, including collagen coating records, indicated that the graft was processed and inspected according to procedures and no anomaly was found.Specifically, the review of the water permeability testing records of products coated on the same day and under the same conditions as the complaint device indicated values well within product specifications.One retention sample coated on the same period and under the same conditions as the complaint device underwent water permeability testing at 120mmhg as per iso 7198.The test result indicated a value well within product specifications.No conclusion can be drawn.However, all available information and the product testing performed would tend to indicate that the device was not defective.The clinical details have been forwarded to the vice president, medical affairs, a former cardiac surgeon.From his analysis, the device likely played no role in the patient death.Most likely the event should be attributed to an unbalanced coagulation cascade induced by the complexity of the procedure, hypothermia and extended extra-circulatory support.
 
Event Description
During an arch replacement performed on (b)(6) 2015 to repair an aortic dissection, it was reported that the patient experienced intraoperative bleeding especially through the needle holes (500-600 ml/h).Platelet and coagulation factor were used to stop the bleeding.The duration of the operation was about 3 hours with nothing abnormal.Unfortunately, the hemostatic effect was not good, the patient eventually died of hemorrhagic shock.Additional clinical information indicated that anticoagulant medication was used before surgery, the act range during extracorporeal circulation was extremely high and the platelet data of the patient was low.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
INTERGARD WOVEN AORTIC ARCH
Type of Device
VASCULAR GRAFT PROSTHESIS
Manufacturer (Section D)
INTERVASCULAR SAS
zi athelia 1
la ciotat cedex, 13705
FR  13705
Manufacturer (Section G)
INTERVASCULAR SAS
zi athelia 1
la ciotat cedex, 13705
FR   13705
Manufacturer Contact
pascal de framond
zi athélia 1
la ciotat cedex, 13705
FR   13705
3344208134
MDR Report Key5293011
MDR Text Key33391343
Report Number1640201-2015-00044
Device Sequence Number1
Product Code DSY
UDI-Device Identifier00384401010739
UDI-Public00384401010739
Combination Product (y/n)N
Reporter Country CodeCH
PMA/PMN Number
K013651
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,distri
Reporter Occupation Physician
Type of Report Initial
Report Date 11/24/2015
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received12/14/2015
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator No Information
Device Expiration Date02/28/2019
Device Model NumberHEWAA2410080810/1
Device Catalogue NumberHEWAA2410080810/1
Device Lot Number14C27
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received11/24/2015
Was Device Evaluated by Manufacturer? No
Date Device Manufactured03/01/2014
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
HEPARIN
Patient Outcome(s) Other;
-
-